These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38753112)

  • 21. Treatment with dalbavancin in a patient with septic thrombophlebitis of the internal jugular vein due to Staphylococcus aureus after insertion of an implantable cardioverter defibrillator.
    Martínez-Sanz J; Gijón de la Santa L; Torralba M
    Enferm Infecc Microbiol Clin (Engl Ed); 2018; 36(6):389-390. PubMed ID: 29132942
    [No Abstract]   [Full Text] [Related]  

  • 22. A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study.
    Pascale R; Maccaro A; Mikus E; Baldassarre M; Tazza B; Esposito F; Rinaldi M; Tenti E; Ambretti S; Albertini A; Viale P; Giannella M; Bartoletti M
    J Glob Antimicrob Resist; 2022 Sep; 30():390-394. PubMed ID: 35878780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppressive antibiotic therapy in prosthetic joint infections: a multicentre cohort study.
    Escudero-Sanchez R; Senneville E; Digumber M; Soriano A; Del Toro MD; Bahamonde A; Del Pozo JL; Guio L; Murillo O; Rico A; García-País MJ; Rodríguez-Pardo D; Iribarren JA; Fernández M; Benito N; Fresco G; Muriel A; Ariza J; Cobo J
    Clin Microbiol Infect; 2020 Apr; 26(4):499-505. PubMed ID: 31539638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppressive antibiotic therapy with oral doxycycline for Staphylococcus aureus prosthetic joint infection: a retrospective study of 39 patients.
    Pradier M; Nguyen S; Robineau O; Titecat M; Blondiaux N; Valette M; Loïez C; Beltrand E; Dézeque H; Migaud H; Senneville E
    Int J Antimicrob Agents; 2017 Sep; 50(3):447-452. PubMed ID: 28668689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
    Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
    Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.
    Matt M; Duran C; Courjon J; Lotte R; Moing VL; Monnin B; Pavese P; Chavanet P; Khatchatourian L; Tattevin P; Cattoir V; Lechiche C; Illes G; Lacassin-Beller F; Senneville E; Dinh A;
    J Glob Antimicrob Resist; 2021 Jun; 25():341-345. PubMed ID: 33962065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
    Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
    Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility.
    Almangour TA; Perry GK; Terriff CM; Alhifany AA; Kaye KS
    Diagn Microbiol Infect Dis; 2019 Mar; 93(3):213-218. PubMed ID: 30396697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.
    Kussmann M; Obermueller M; Berndl F; Reischer V; Veletzky L; Burgmann H; Poeppl W
    Sci Rep; 2018 Jun; 8(1):9661. PubMed ID: 29941909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Suppressive antibiotic treatment with dalbavancin. A case report].
    Barbero Allende JM; García Sánchez M; Culebras López AM; Agudo Alonso R
    Rev Esp Quimioter; 2021 Apr; 34(2):151-153. PubMed ID: 33491409
    [No Abstract]   [Full Text] [Related]  

  • 33. Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion.
    Rappo U; Dunne MW; Puttagunta S; Baldassarre JS; Su S; Desai-Krieger D; Inoue M
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31501147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppressive antibiotic therapy with oral tetracyclines for prosthetic joint infections: a retrospective study of 78 patients.
    Pradier M; Robineau O; Boucher A; Titecat M; Blondiaux N; Valette M; Loïez C; Beltrand E; Nguyen S; Dézeque H; Migaud H; Senneville E
    Infection; 2018 Feb; 46(1):39-47. PubMed ID: 29052797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
    Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
    N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dalbavancin use in an academic medical centre and associated cost savings.
    Streifel AC; Sikka MK; Bowen CD; Lewis JS
    Int J Antimicrob Agents; 2019 Nov; 54(5):652-654. PubMed ID: 31398481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections.
    Gatti M; Viale P; Cojutti PG; Zamparini E; De Paolis M; Giannella M; Pea F; Tedeschi S
    Int J Antimicrob Agents; 2023 May; 61(5):106773. PubMed ID: 36878410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
    Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S
    Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects.
    Scoble PJ; Owens RC; Puttagunta S; Yen M; Dunne MW
    Clin Drug Investig; 2015 Dec; 35(12):785-93. PubMed ID: 26458939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
    Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.